Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a next-generation biotechnology company and one of the world’s first fully vertically-integrated molecular testing platforms.
Specializing in polymerase chain reaction (PCR)-based infectious disease detection, OSPRI develops and delivers advanced tools that improve access to high-quality care across key healthcare segments, including women’s health, primary care, urgent care, urology, hospitals, and clinical reference laboratories.
In addition to assay development, OSPRI delivers an end-to-end solution—covering manufacturing, lab buildout, revenue cycle management, and regulatory support—empowering providers to operate high-complexity labs in-house with greater speed, accuracy, and financial control.
The merger is financed by up to $30 million of strategic funding from Catalio Capital Management. This partnership will support OSPRI’s continued growth, platform development, and national expansion.
OSPRI’s scientific leadership includes Dr. Rahul Sharma (Chief Science Officer), Dr. Sadia Almas (Chief Innovation Officer), and Dr. Alaina Vincent (Chief Clinical Officer). The company’s technology aims to redefine PCR testing through:
- 20–50% reduction in overall testing costs
- 50–70% decrease in testing time and workflow steps
- Up to 4x increase in testing capacity
- Customized assays tailored to provider specialty and patient population
- Reduced lab errors through simplified workflows
- A comprehensive menu of 80+ PCR tests covering 250+ pathogens and AMR genes
Visit OSPRI for more news
